

a.) Remarks

In the outstanding Office Action, the Examiner required that Applicants elect for prosecution one of the inventions of:

Group I (Claims 1, 3-19, 38 and 42), drawn to compositions and compounds;

Group II (Claims 20-37 and 46), drawn to a kit; or

Group III (Claims 41 and 48), drawn to method of treatment.

In response, Applicants hereby elect to prosecute the invention of Group I, namely Claims 1, 3-19, 38 and 42.

Also, the Examiner required that Applicants select a specie among Groups I-III noted at page 3 of the Office Action. Therein, for Group I, the Examiner requests identification of a single specific compound or composition “including an exact definition of each component.” In response, Applicants wish to identify the composition disclosed in Test Example 2 at specification page 33 et seq. as a single species for the composition.

Test Example 2 comprises (a) Compound (I) and (b) fluoxetine hydrochloride. See from specification page 19, line 30 to page 20, line 4 and Table 3 at page 36.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/
Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

FCHS_WS 2741758_1.DOC